Mark Chalmers | Partner, Life Sciences Commercial Access

Mark Chalmers, Partner, Life Sciences Commercial Access, EY

Mark Chalmers is a Partner in the EY Life Sciences Commercial Access team, with more than 15 years of experience specialising in global commercial and launch strategy, including international pricing and market access for pharmaceutical and biotech companies. He has global experience of healthcare systems and health technology assessment, with a deep knowledge of oncology, immunology, rare diseases, Advanced Therapy Medicinal Products (ATMPs) and cell and gene based therapies.
Prior to EY, Mark was Principal and EU Lead at CBPartners, Director in Navigant’s Life science practice and a Director at Simon-Kucher & Partners.
Mark works closely with clients in the pharmaceutical and biotech industries to address critical commercial strategic issues and support business development and licensing decisions.


Day 3: Friday 21st May 2021 - Commercialisation, Pricing & Access @ 13:30

Overcoming pain points in the CGT value chain by creating a scalable and collaborative ecosystem

·This session will feature interviews with leaders in Biopharma and logistics as they discuss their pain points as they move cell and gene therapies into commercialization.
last published: 10/May/21 08:45 GMT

back to speakers